Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • exagamglogene autotemcel

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

    The rare inherited disease affects approximately 11,000 people in the UK

    - PMLiVE

    Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval

    The rare inherited disease affects more than 109,000 people worldwide

    - PMLiVE

    GSK’s Blenrep combination recommended by NICE to treat multiple myeloma

    The decision means that eligible patients in England will be the first in the world to access the combination

    - PMLiVE

    NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis

    Around 1,000 patients could benefit from the relugolix combination therapy every year

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

    Over 11,000 people in the UK are affected by the rare genetic disease

    - PMLiVE

    Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

    Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

    - PMLiVE

    NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

    About 15,000 people in England are living with the inherited blood disorder

    - PMLiVE

    AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi

    More than 49,000 people are diagnosed with lung cancer in the UK each year

    - PMLiVE

    NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

    Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

    - PMLiVE

    NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer

    More than 100 patients are expected to be eligible for the treatment every year

    - PMLiVE

    NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder

    Systemic mastocytosis affects approximately one in every 10,000 people in the UK

    - PMLiVE

    Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma

    Approximately 5,000 people are diagnosed with the disease every year in England

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links